Antibodies News and Research

RSS

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.

2 Mar 2013

Exposure to BPA may increase risk of asthma in young children

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to report an association between early childhood exposure to the chemical bisphenol A (BPA) and an elevated risk for asthma in young children. BPA is a component of some plastics and is found in food can liners and store receipts.

1 Mar 2013

Anti-LG3 associated with high rate of organ rejection during transplantation

A team led by Dr. Marie-Jos-e H-bert from the University of Montreal Hospital* Research Centre (CRCHUM) has discovered a new cause of organ rejection in some kidney transplant patients. Her team has identified a new class of antibodies - anti-LG3 - which when activated lead to severe rejection episodes associated with a high rate of organ loss.

28 Feb 2013

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at specifically targeting and delivering anti-cancer drugs to breast cancer cells.

28 Feb 2013

MenB bacterium uses Adhesin Complex Protein to stick to human cells

Scientists at the University of Southampton have taken a significant and important step in keeping people safe from the most common form of meningitis in the UK.

28 Feb 2013

XBiotech to enter biosimilar business

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product.

26 Feb 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Natalizumab may be second-line option for pediatric MS patients

Natalizumab may be an effective and well tolerated second-line treatment for pediatric patients with highly active relapsing-remitting multiple sclerosis, say researchers.

26 Feb 2013

Researchers improve NanoVelcro device to better grab cancer cells as blood passes by them

Researchers at UCLA report that they have refined a method they previously developed for capturing and analyzing cancer cells that break away from patients' tumors and circulate in the blood. With the improvements to their device, which uses a Velcro-like nanoscale technology, they can now detect and isolate single cancer cells from patient blood samples for analysis.

26 Feb 2013

Protamine–heparin complex antibodies raise concerns

Almost a third of patients treated with protamine for heparin reversal during cardiopulmonary bypass develop antibodies to circulating protamine–heparin complexes, study findings suggest.

25 Feb 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

Two USC scientists develop new algorithm to help predict value of DNA sequencing

Two USC scientists have developed an algorithm that could help make DNA sequencing affordable enough for clinics - and could be useful to researchers of all stripes.

25 Feb 2013

Antibody delivery system launched that works even in presence of additives

...

22 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Inspiration Biopharmaceuticals and Ipsen today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation.

20 Feb 2013

SQI Diagnostics reports net loss of $1,563,000 for quarter-ended December 31, 2012

SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the first quarter-ended December 31, 2012.

15 Feb 2013

Regeneron fourth quarter total revenues increase to $415 million

Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

14 Feb 2013

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

13 Feb 2013

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

13 Feb 2013

Infusions of regulatory T cells turn off autoimmune attack on joints

Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.

10 Feb 2013

Antibodies News and Research

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Exposure to BPA may increase risk of asthma in young children

Anti-LG3 associated with high rate of organ rejection during transplantation

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

MenB bacterium uses Adhesin Complex Protein to stick to human cells

XBiotech to enter biosimilar business

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Natalizumab may be second-line option for pediatric MS patients

Researchers improve NanoVelcro device to better grab cancer cells as blood passes by them

Protamine–heparin complex antibodies raise concerns

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

Two USC scientists develop new algorithm to help predict value of DNA sequencing

Antibody delivery system launched that works even in presence of additives

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

SQI Diagnostics reports net loss of $1,563,000 for quarter-ended December 31, 2012

Regeneron fourth quarter total revenues increase to $415 million

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

Infusions of regulatory T cells turn off autoimmune attack on joints

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News